FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2018202764> ?p ?o ?g. }

• W2018202764 endingPage "1630" @default.
• W2018202764 startingPage "1621" @default.
• W2018202764 abstract "The objective of this study was to investigate the safety and efficacy of recombinant human insulinlike growth factor-I (rhIGF-I) in the treatment of sporadic ALS. A double-blind, placebo-controlled, randomized study of 266 patients was conducted at eight centers in North America. Placebo or rhIGF-I (0.05 mg/kg/day or 0.10 mg/kg/day) was administered for 9 months. The primary outcome measure was disease symptom progression, assessed by the rate of change (per patient slope) in the Appel ALS rating scale total score. The Sickness Impact Profile (SIP), a patient-perceived, health-related quality of life assessment, was a secondary outcome variable. Progression of functional impairment in patients receiving high-dose (0.10 mg/kg/day) rhIGF-I was 26% slower than in patients receiving placebo (p = 0.01). The high-dose treatment group was less likely to terminate the study due to protocol-defined markers of disease symptom progression, and members in this group exhibited a slower decline in quality of life, as assessed by the SIP. Patients receiving 0.05 mg/kg/day of rhIGF-I exhibited trends similar to those associated with high-dose treatment, suggesting a dose-dependent response. The incidence of clinically significant adverse experiences was comparable among the three treatment groups. Recombinant human insulin-like growth factor-I slowed the progression of functional impairment and the decline in health-related quality of life in patients with ALS with no medically important adverse effects." @default.
• W2018202764 created "2016-06-24" @default.
• W2018202764 creator A5004383772 @default.
• W2018202764 creator A5013039110 @default.
• W2018202764 creator A5014513006 @default.
• W2018202764 creator A5020836953 @default.
• W2018202764 creator A5028058961 @default.
• W2018202764 creator A5048221931 @default.
• W2018202764 creator A5070475275 @default.
• W2018202764 creator A5086605930 @default.
• W2018202764 creator A5089599601 @default.
• W2018202764 creator A5090297236 @default.
• W2018202764 date "1997-12-01" @default.
• W2018202764 modified "2023-10-16" @default.
• W2018202764 title "Effect of recombinant human insulin-like growth factor-I on progression of ALS: A placebo-controlled study" @default.
• W2018202764 cites W1967159615 @default.
• W2018202764 cites W2101032749 @default.
• W2018202764 cites W2119644933 @default.
• W2018202764 cites W2316360032 @default.
• W2018202764 cites W2576914777 @default.
• W2018202764 doi "https://doi.org/10.1212/wnl.49.6.1621" @default.
• W2018202764 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/9409357" @default.
• W2018202764 hasPublicationYear "1997" @default.
• W2018202764 type Work @default.
• W2018202764 sameAs 2018202764 @default.
• W2018202764 citedByCount "334" @default.
• W2018202764 countsByYear W20182027642012 @default.
• W2018202764 countsByYear W20182027642013 @default.
• W2018202764 countsByYear W20182027642014 @default.
• W2018202764 countsByYear W20182027642015 @default.
• W2018202764 countsByYear W20182027642016 @default.
• W2018202764 countsByYear W20182027642017 @default.
• W2018202764 countsByYear W20182027642018 @default.
• W2018202764 countsByYear W20182027642019 @default.
• W2018202764 countsByYear W20182027642020 @default.
• W2018202764 countsByYear W20182027642021 @default.
• W2018202764 countsByYear W20182027642022 @default.
• W2018202764 countsByYear W20182027642023 @default.
• W2018202764 crossrefType "journal-article" @default.
• W2018202764 hasAuthorship W2018202764A5004383772 @default.
• W2018202764 hasAuthorship W2018202764A5013039110 @default.
• W2018202764 hasAuthorship W2018202764A5014513006 @default.
• W2018202764 hasAuthorship W2018202764A5020836953 @default.
• W2018202764 hasAuthorship W2018202764A5028058961 @default.
• W2018202764 hasAuthorship W2018202764A5048221931 @default.
• W2018202764 hasAuthorship W2018202764A5070475275 @default.
• W2018202764 hasAuthorship W2018202764A5086605930 @default.
• W2018202764 hasAuthorship W2018202764A5089599601 @default.
• W2018202764 hasAuthorship W2018202764A5090297236 @default.
• W2018202764 hasConcept C104317684 @default.
• W2018202764 hasConcept C120665830 @default.
• W2018202764 hasConcept C121332964 @default.
• W2018202764 hasConcept C126322002 @default.
• W2018202764 hasConcept C142724271 @default.
• W2018202764 hasConcept C159110408 @default.
• W2018202764 hasConcept C170493617 @default.
• W2018202764 hasConcept C197934379 @default.
• W2018202764 hasConcept C204787440 @default.
• W2018202764 hasConcept C27081682 @default.
• W2018202764 hasConcept C2775960820 @default.
• W2018202764 hasConcept C2779134260 @default.
• W2018202764 hasConcept C2779951463 @default.
• W2018202764 hasConcept C2780689927 @default.
• W2018202764 hasConcept C40767141 @default.
• W2018202764 hasConcept C535046627 @default.
• W2018202764 hasConcept C55493867 @default.
• W2018202764 hasConcept C61511704 @default.
• W2018202764 hasConcept C71924100 @default.
• W2018202764 hasConcept C86803240 @default.
• W2018202764 hasConceptScore W2018202764C104317684 @default.
• W2018202764 hasConceptScore W2018202764C120665830 @default.
• W2018202764 hasConceptScore W2018202764C121332964 @default.
• W2018202764 hasConceptScore W2018202764C126322002 @default.
• W2018202764 hasConceptScore W2018202764C142724271 @default.
• W2018202764 hasConceptScore W2018202764C159110408 @default.
• W2018202764 hasConceptScore W2018202764C170493617 @default.
• W2018202764 hasConceptScore W2018202764C197934379 @default.
• W2018202764 hasConceptScore W2018202764C204787440 @default.
• W2018202764 hasConceptScore W2018202764C27081682 @default.
• W2018202764 hasConceptScore W2018202764C2775960820 @default.
• W2018202764 hasConceptScore W2018202764C2779134260 @default.
• W2018202764 hasConceptScore W2018202764C2779951463 @default.
• W2018202764 hasConceptScore W2018202764C2780689927 @default.
• W2018202764 hasConceptScore W2018202764C40767141 @default.
• W2018202764 hasConceptScore W2018202764C535046627 @default.
• W2018202764 hasConceptScore W2018202764C55493867 @default.
• W2018202764 hasConceptScore W2018202764C61511704 @default.
• W2018202764 hasConceptScore W2018202764C71924100 @default.
• W2018202764 hasConceptScore W2018202764C86803240 @default.
• W2018202764 hasIssue "6" @default.
• W2018202764 hasLocation W20182027641 @default.
• W2018202764 hasLocation W20182027642 @default.
• W2018202764 hasOpenAccess W2018202764 @default.
• W2018202764 hasPrimaryLocation W20182027641 @default.
• W2018202764 hasRelatedWork W2000727265 @default.
• W2018202764 hasRelatedWork W2038000824 @default.
• W2018202764 hasRelatedWork W2064879719 @default.
• W2018202764 hasRelatedWork W2085830368 @default.

• next